Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Deciphera Pharmaceuticals, Inc.
< Previous
1
2
Next >
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
May 25, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
May 08, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
May 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
April 26, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
April 19, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18
March 14, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
March 01, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
February 07, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 02, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
January 31, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 24, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
January 24, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 19, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 18, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
January 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
January 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
December 01, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
November 08, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
November 03, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
October 27, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
September 11, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022
September 10, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
September 01, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
August 10, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
August 04, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Tickers
DCPH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.